Glaukos Corporation $GKOS Shares Sold by Legal & General Group Plc

Legal & General Group Plc cut its position in shares of Glaukos Corporation (NYSE:GKOS) by 5.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 179,698 shares of the medical instruments supplier’s stock after selling 9,578 shares during the quarter. Legal & General Group Plc’s holdings in Glaukos were worth $20,290,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of the stock. Wellington Management Group LLP grew its holdings in shares of Glaukos by 10.4% in the 3rd quarter. Wellington Management Group LLP now owns 3,580,670 shares of the medical instruments supplier’s stock worth $292,004,000 after acquiring an additional 336,266 shares during the last quarter. Primecap Management Co. CA grew its holdings in shares of Glaukos by 23.3% in the 3rd quarter. Primecap Management Co. CA now owns 2,253,788 shares of the medical instruments supplier’s stock worth $183,796,000 after acquiring an additional 425,790 shares during the last quarter. State Street Corp grew its holdings in shares of Glaukos by 5.3% in the 2nd quarter. State Street Corp now owns 2,090,365 shares of the medical instruments supplier’s stock worth $215,914,000 after acquiring an additional 105,972 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Glaukos by 3.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,999,252 shares of the medical instruments supplier’s stock worth $206,503,000 after acquiring an additional 68,497 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of Glaukos by 38.5% in the 3rd quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock worth $141,365,000 after acquiring an additional 481,620 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Stifel Nicolaus set a $170.00 target price on Glaukos in a report on Thursday, April 30th. JPMorgan Chase & Co. lifted their target price on Glaukos from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Wells Fargo & Company lifted their target price on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a report on Thursday, April 30th. Wall Street Zen cut Glaukos from a “buy” rating to a “hold” rating in a report on Saturday. Finally, William Blair restated an “outperform” rating on shares of Glaukos in a report on Tuesday, May 26th. Twelve equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $146.17.

Insider Transactions at Glaukos

In related news, Director Leana Wen sold 1,700 shares of Glaukos stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.35, for a total transaction of $243,695.00. Following the completion of the sale, the director owned 19,739 shares of the company’s stock, valued at approximately $2,829,585.65. This trade represents a 7.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $140.76, for a total value of $703,800.00. Following the sale, the director directly owned 35,528 shares of the company’s stock, valued at approximately $5,000,921.28. The trade was a 12.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 45,930 shares of company stock worth $6,321,363 in the last ninety days. Company insiders own 5.90% of the company’s stock.

Glaukos Price Performance

GKOS opened at $103.08 on Monday. The stock has a market cap of $6.05 billion, a price-to-earnings ratio of -31.43 and a beta of 0.83. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $148.11. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. The stock has a fifty day moving average price of $121.31 and a 200 day moving average price of $114.45.

Glaukos (NYSE:GKOS) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.12. The firm had revenue of $150.57 million during the quarter, compared to analysts’ expectations of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The business’s revenue for the quarter was up 41.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.22) earnings per share. Analysts forecast that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.